Important notice regarding Rhopressa

Posted in Latest News on February 12, 2019.

The board approved Rhopressa (netarsudil ophthalmic solution) 0.02% for addition to Rule 64B13-18.002. Effective January 25, 2019, Licensees are now permitted to prescribe Rhopressa.



More Latest News

Third Quarter Performance Report
June 14, 2022

Released for the
2021 – 2022 Fiscal Year Continue reading


Topical Ocular Pharmaceutical Agents added to Formulary
May 27, 2022

The Board of Optometry has added the following Topical Ocular Pharmaceutical Agents to the formulary… Continue reading